Bodycote上半年EPS小幅超预期但全年指引维持不变

S. Korea stocks slump over 10% as AI spending fears hammer chip stocks
Introduction & Market Context
Bodycote plc (LSE:BOY) presented its first-half 2026 results on July 28, revealing strong momentum in aerospace and defense markets that helped drive earnings per share growth of 18.3% despite ongoing challenges in the automotive sector. The thermal processing specialist reported adjusted EPS of 25.2p, narrowly beating analyst forecasts of 25.1p, as core organic revenue growth of 9.6% translated into expanding margins and improved profitability.
The company’s stock rose 1.5% to $699.32 following the results, building on an 82% gain over the past year. With current trading at $699.32, shares remain approximately 17% below their 52-week high of $845 but well above the low of $572.50, reflecting investor confidence in the company’s strategic transformation despite broader macroeconomic uncertainties.
Quarterly Performance Highlights
Bodycote’s first-half performance demonstrated the company’s successful pivot toward higher-growth end markets. As shown in the following summary of key achievements, the company delivered results in line with expectations across multiple metrics.
Group revenue reached £381.2 million in the first half, representing 6.5% organic growth and 3.3% total growth compared to the prior year period. The core business, which excludes non-core sites targeted for exit under the Optimise restructuring program, performed even more strongly with 9.6% organic growth and 10.5% total growth to £372.0 million.
The following chart illustrates the strong core growth trajectory, with aerospace and defense leading the recovery from a soft first-half 2025 comparator.
Aerospace and defense emerged as the standout performer, with organic revenue growth of 24.6% driven by strong demand across both original equipment and aftermarket segments. This segment now represents 38% of total core revenue, up significantly from previous periods. Industrial gas turbines within the energy sector also showed robust growth of 10.3%, while the medical segment returned to growth after prior weakness.
These gains were partially offset by a 4.4% decline in automotive revenue, which management characterized as facing "challenging conditions in Western Europe" and structural headwinds. The automotive segment now accounts for 20% of core revenue, down from higher historical levels as the company actively reshapes its portfolio.
Detailed Financial Analysis
The company’s margin performance exceeded expectations, with core operating margins expanding 30 basis points to 16.2% and group margins improving 110 basis points to 16.0%. The following detailed financial summary shows the progression across both core and group metrics.
Core adjusted operating profit increased 11.0% organically to £60.4 million, while group adjusted operating profit rose 12.9% organically to £61.0 million. Management noted that margin expansion occurred "despite variable pay headwind and growth ramp-up costs," indicating strong underlying operational performance.
The drivers of profit growth are illustrated in the following waterfall analysis, which breaks down the £5.9 million increase in adjusted operating profit from H1 2025 to H1 2026.
Specialist Technologies led profit growth with a £4.6 million contribution, followed by Precision Heat Treatment adding £2.4 million. These gains were partially offset by a £1.0 million reduction from non-core operations as the company continues exiting underperforming sites, and a £0.5 million increase in central costs.
The earnings per share growth of 18.3% outpaced revenue growth significantly, reflecting both operational leverage and the impact of the company’s ongoing £80 million share buyback program. Approximately 1.9 million shares were acquired in the first half at a volume-weighted average price of 680p, with £12.6 million deployed.
Strategic Transformation Progress
Bodycote’s three-pillar strategy—Optimise, Perform, and Grow—continued to deliver tangible benefits in the first half. The Optimise program, focused on consolidating underperforming sites, has now completed 27 of 31 planned exits and is delivering approximately £8 million in annual profit benefits for 2026.
The following summary shows how the Optimise program is enabling simultaneous cost reduction and revenue growth.
The company has achieved a 3% increase in revenue alongside a 6% increase in organic revenue, while reducing labor costs by 1% and utility costs by 2%. Energy intensity has improved by approximately 11%, and headcount has declined by roughly 4%. Importantly, the company has retained more than 25% of revenue from exited sites, demonstrating successful customer migration.
Management indicated it is "exploring potential options to expand the scope of the programme, focused on more structurally challenged Automotive sites," with a decision expected within the next one to two months. While acknowledging that any expanded program would likely have "a less attractive payback than the first," executives believe it would still generate reasonable returns.
The Perform initiative, launched to drive operational excellence, has established four "Lighthouse" sites that will serve as regional training hubs. The following details show the progress and targets for these operational improvement centers.
The first Lighthouse site, a U.S. HIP (Hot Isostatic Pressing) product fabrication facility launched in April 2026, targets a 50% reduction in turnaround time, 75% reduction in new product introduction lead time, and margin improvement exceeding 300 basis points. Early progress includes three kaizen events completed and new product introduction lead time reduced by approximately 30%.
Three additional Lighthouse sites launched between March and July 2026, targeting margin improvements ranging from 175 to 250 basis points. Management "remains confident in ~100bps margin improvement from Perform by 2028" as these improvements roll out across the company’s more than 100 sites globally.
Segment Performance Deep Dive
Specialist Technologies, which includes advanced processes like HIP and vacuum heat treatment, delivered exceptional growth in the first half. The following breakdown shows the segment’s financial performance and end market composition.
Revenue in Specialist Technologies reached £121.2 million, up 16.7% organically, with adjusted operating margin of 26.1%. Aerospace and defense now represents approximately 50% of this segment’s revenue, growing 37.1% organically. Management highlighted that "two material A&D LTAs [Long-Term Agreements] renewed with additional volumes," providing enhanced revenue visibility.
Medical returned to growth with 15.7% expansion in the Consumer, Medical & Other category, while industrial gas turbines grew 16.9%. Only automotive showed weakness in this segment, declining 5.7%.
Precision Heat Treatment, the company’s larger segment focused on conventional heat treatment processes, also demonstrated solid growth. The following analysis details this segment’s performance across end markets.
Precision Heat Treatment generated £250.8 million in revenue, up 6.4% organically, with margins stable at 15.0%. The segment benefited from "strong Commercial Aerospace growth in the UK and US" with defense up 6.0% "led by demand in North America." Industrial markets showed modest growth of 3.6%, partly benefiting from revenue transfers under the Optimise program, while automotive declined 4.3% with "softness in Western Europe and China."
Management noted that margins remained stable as "volume growth offset by variable pay headwind and temporary ramp-up costs relating to new A&D investments," suggesting potential for margin expansion once these investments mature.
Cash Flow and Capital Allocation
Operating cash flow performance remained solid, with adjusted operating cash flow increasing to £41.6 million from £37.7 million in the prior year period. The following detailed cash flow statement shows the progression from operating profit to free cash flow.
Cash conversion remained stable at 68%, though free cash flow declined to £14.5 million from £18.0 million due to higher restructuring spending of £9.5 million and increased cash tax payments of £13.6 million. Management expects full-year cash tax of approximately £25 million.
Net capital expenditure declined to £33.5 million from £38.0 million, with management now guiding to approximately £80 million for the full year, at the lower end of the previous £80-90 million range. The company noted that "capex investment expected to increase in H2 to support growth strategy," particularly for aerospace and defense capacity expansion.
The company’s capital allocation priorities remained balanced across growth investment, shareholder returns, and debt management, as illustrated in the following summary.
Net debt excluding leases stood at £135.2 million at period-end, representing leverage of 0.7x net debt/EBITDA. The company deployed £27.5 million in ordinary dividends, with the interim dividend increasing 4% to 7.2p per share. The £80 million share buyback program is progressing as planned, with £17.8 million spent in the first half including £12.6 million under the new program announced in 2026.
The Spectrum acquisition, completed in January 2026 for £5.5 million, was described as "successfully integrated and performing well," adding aerospace and defense capability in North America. Management emphasized its preference for building relationships with family-owned businesses rather than participating in competitive auctions, noting the company "aims to do several acquisitions a year" as it builds its M&A pipeline.
Portfolio Transformation
A central theme of the presentation was Bodycote’s ongoing shift toward higher-growth, higher-margin end markets. The following visualization demonstrates the dramatic portfolio evolution over the past two years.
Higher growth end markets—aerospace, defense, industrial gas turbines, medical, and electronics—now account for 48% of group revenue, up from 35% in fiscal 2023. This 13-percentage-point shift reflects multiple strategic actions including the exit of 27 non-core sites, acquisitions of Lake City and Spectrum, and targeted investments in aerospace and defense growth projects.
Management outlined four drivers to continue this mix shift: strong underlying growth in target markets, organic acceleration and investment, targeted M&A bolt-ons, and potential further consolidations or exits. The company is actively exploring expansion of the Optimise program to address "more structurally challenged Automotive sites," which could further accelerate the portfolio transformation.
Forward-Looking Statements and Guidance
Bodycote reaffirmed its full-year 2026 outlook, stating it remains "unchanged, mindful of the current geopolitical and macroeconomic environment." The following detailed guidance table shows updated technical assumptions for the full year.
Key guidance updates include:
- Non-core revenue expected at £12-15 million, down from prior guidance of approximately £15 million
- Capital expenditure now expected at approximately £80 million, down from £80-90 million
- P&L net finance charge reduced to approximately £10 million from £11 million
- Adjusted tax rate lowered to approximately 23.5% from 24.5%
- Weighted average share count of approximately 170 million shares
Management expects to "deliver Core organic revenue growth led by A&D, IGT, and Medical; partly offset by continued Automotive weakness." However, the "pace of growth expected to moderate in H2 due to tougher prior year comparators," particularly in aerospace and defense where first-half comparisons were unusually favorable.
The company anticipates group margin improvement "supported by growing Optimise benefits, despite variable pay headwind and growth ramp-up costs." Variable pay normalization reflects a return to normal bonus levels after subdued 2025 payments, while ramp-up costs relate to new aerospace and defense capacity investments that have not yet reached full utilization.
The following outlook summary encapsulates management’s expectations for the remainder of 2026.
Chief Executive Jim Fairbairn stated the company is "on track and pleased with progress in the first half," expressing confidence in delivering medium-term financial targets. These targets include mid-single-digit organic revenue growth through the cycle and approximately 100 basis points of margin improvement from the Perform program by 2028.
Chief Financial Officer Ben Fidler highlighted the "strong 18.3%" EPS growth and noted expectations for continued group margin expansion despite near-term headwinds. The company’s strategic framework focuses on "continued deployment of Perform & Grow initiatives to create a higher quality, more resilient and faster growing Bodycote."
Risk Factors and Challenges
While the first-half results demonstrated strong progress, management acknowledged several ongoing challenges. Automotive markets remain "structurally challenged" with particular weakness in Western Europe and China, where electric vehicle adoption and changing powertrain architectures are reducing demand for traditional heat treatment services.
The aerospace and defense growth rate, while impressive at 24.6%, is expected to moderate in the second half due to tougher year-over-year comparisons. Management emphasized that while growth will continue, the exceptional pace seen in the first half is not sustainable.
Free cash flow declined year-over-year due to higher restructuring spending and increased tax payments, a trend that may continue as the company considers expanding the Optimise program. Working capital increased by £12.6 million, reflecting revenue growth and timing effects, with management noting this as a normal pattern that should reverse over the full year.
Execution risk remains around the potential expansion of the Optimise program, which would target more automotive sites. Management acknowledged this next phase would likely deliver "a less attractive payback than the first" but maintains it would still generate reasonable returns. A decision on program expansion is expected within the next one to two months.
The company also faces ongoing margin pressure from variable pay normalization and ramp-up costs on new growth investments, headwinds that are expected to persist through the second half of 2026 before easing in 2027.
Despite these challenges, management’s decision to reaffirm full-year guidance and maintain its medium-term targets suggests confidence in the underlying business trajectory and the strategic transformation underway.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.